TABLE 2

Contribution of UGT1A4, UGT1A9, and UGT2B7 to haloperidol O-glucuronidation in HLM

Human LiverHL1HL2HL3HL4HL5HL6Average
RAFUGT
    1A41.850.911.280.720.910.661.05
    1A90.480.410.170.470.240.440.37
    2B71.160.641.281.221.290.941.09
25 μM Haloperidol
    Vobs (nmol · min−1 · mg−1)0.0690.0420.0910.0830.080.0540.070
    Vest (nmol · min−1 · mg−1) (% contribution)
    UGT1A40.016 (23.3)0.008 (18.9)0.011 (12.2)0.006 (7.5)0.008 (9.9)0.006 (10.6)0.009 (13.7)
    UGT1A90.017 (24.6)0.014 (34.5)0.006 (6.6)0.017 (20.0)0.008 (10.6)0.016 (28.8)0.013 (20.9)
    UGT2B70.061 (88.9)0.034 (80.6)0.068 (74.4)0.065 (77.8)0.068 (85.3)0.050 (92.1)0.058 (83.2)
100 μM Haloperidol
    Vobs (nmol · min−1 · mg−1)
    Vobs0.1740.1030.1560.1560.0790.1400.135
    Vest (nmol · min−1 · mg−1) (% contribution)
    UGT1A40.043 (24.9)0.021 (20.7)0.030 (19.2)0.017 (10.8)0.021 (27.0)0.015 (11.0)0.025 (18.9)
    UGT1A90.047 (26.8)0.040 (38.7)0.017 (10.6)0.046 (29.3)0.023 (29.5)0.043 (30.5)0.036 (27.6)
    UGT2B70.089 (51.2)0.049 (47.7)0.098 (63.0)0.094 (60.1)0.099 (125.4)0.072 (51.6)0.085 (66.5)
200 μM Haloperidol
    Vobs (nmol · min−1 · mg−1)0.2600.1400.2130.2260.2290.2020.212
    Vest (nmol · min−1 · mg−1) (% contribution)
    UGT1A40.071 (27.3)0.035 (24.9)0.049 (23.0)0.028 (12.2)0.035 (15.2)0.025 (12.5)0.041 (19.2)
    UGT1A90.062 (23.8)0.053 (37.7)0.022 (10.3)0.060 (26.8)0.031 (13.5)0.057 (28.0)0.048 (23.4)
    UGT2B70.096 (37.1)0.053 (38.0)0.106 (49.9)0.101 (44.9)0.107 (46.8)0.078 (38.7)0.090 (42.6)